Haemonetics Co. (NYSE:HAE) Shares Purchased by Cardinal Capital Management

Cardinal Capital Management boosted its stake in shares of Haemonetics Co. (NYSE:HAE) by 17.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 17,349 shares of the medical instruments supplier’s stock after buying an additional 2,517 shares during the quarter. Cardinal Capital Management’s holdings in Haemonetics were worth $1,395,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in HAE. Goldman Sachs Group Inc. increased its stake in Haemonetics by 14.6% in the 4th quarter. Goldman Sachs Group Inc. now owns 191,253 shares of the medical instruments supplier’s stock valued at $16,354,000 after purchasing an additional 24,394 shares in the last quarter. Quantbot Technologies LP raised its stake in shares of Haemonetics by 2,101.6% during the 1st quarter. Quantbot Technologies LP now owns 14,068 shares of the medical instruments supplier’s stock worth $1,201,000 after buying an additional 13,429 shares during the last quarter. Silvercrest Asset Management Group LLC purchased a new stake in shares of Haemonetics in the 1st quarter worth about $38,706,000. Allspring Global Investments Holdings LLC grew its stake in Haemonetics by 132.8% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 502,993 shares of the medical instruments supplier’s stock valued at $42,930,000 after acquiring an additional 286,897 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its holdings in Haemonetics by 38.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 562,454 shares of the medical instruments supplier’s stock valued at $48,006,000 after acquiring an additional 156,665 shares in the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Haemonetics news, insider Stewart W. Strong sold 4,312 shares of the company’s stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $91.15, for a total transaction of $393,038.80. Following the completion of the sale, the insider now directly owns 18,196 shares in the company, valued at $1,658,565.40. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 1.80% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on HAE. CL King started coverage on shares of Haemonetics in a research report on Friday, September 13th. They issued a “buy” rating and a $116.00 price target on the stock. Bank of America started coverage on Haemonetics in a report on Wednesday, September 11th. They set a “neutral” rating and a $85.00 target price on the stock. Citigroup cut their price target on Haemonetics from $94.00 to $85.00 and set a “neutral” rating for the company in a report on Thursday, August 22nd. Barrington Research reaffirmed an “outperform” rating and set a $108.00 price objective on shares of Haemonetics in a research note on Monday, September 23rd. Finally, BTIG Research began coverage on shares of Haemonetics in a research note on Tuesday, September 10th. They issued a “buy” rating and a $112.00 target price for the company. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, Haemonetics presently has an average rating of “Moderate Buy” and a consensus target price of $106.14.

Haemonetics Stock Up 0.3 %

Shares of NYSE:HAE opened at $76.14 on Friday. The company has a current ratio of 3.76, a quick ratio of 2.33 and a debt-to-equity ratio of 1.35. The firm has a market cap of $3.88 billion, a price-to-earnings ratio of 33.25, a PEG ratio of 1.19 and a beta of 0.30. The stock’s 50-day moving average price is $75.66 and its two-hundred day moving average price is $83.57. Haemonetics Co. has a 12-month low of $70.74 and a 12-month high of $97.97.

Haemonetics (NYSE:HAE) last released its earnings results on Thursday, August 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.03 by ($0.01). Haemonetics had a return on equity of 21.86% and a net margin of 8.61%. The company had revenue of $336.17 million during the quarter, compared to analyst estimates of $335.08 million. During the same period in the prior year, the business posted $1.05 earnings per share. Haemonetics’s revenue was up 8.0% on a year-over-year basis. On average, research analysts forecast that Haemonetics Co. will post 4.57 EPS for the current year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.